Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Open Access
- 20 January 2025
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 100 (4) , 708-711
Abstract
Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.Keywords
Funding Information
- Ministero della Salute
- European Commission
This publication has 8 references indexed in Scilit:
- Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendationsBlood, 2024
- Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxBlood Advances, 2024
- Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemiaHematology, 2023
- Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclaxBritish Journal of Haematology, 2023
- The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical studyCancer Medicine, 2023
- AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaCancer, 2023
- Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of MortalityJAMA Oncology, 2017
- Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision makingLeukemia, 2013